GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Effective Interest Rate on Debt %

Oncodesign Precision Medicine (XPAR:ALOPM) Effective Interest Rate on Debt % : 1.03% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Oncodesign Precision Medicine's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was €0.08 Mil. Oncodesign Precision Medicine's average total debt for the quarter that ended in Dec. 2024 was €7.58 Mil. Therefore, Oncodesign Precision Medicine's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 1.03%.

Oncodesign Precision Medicine Effective Interest Rate on Debt % Historical Data

The historical data trend for Oncodesign Precision Medicine's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Effective Interest Rate on Debt % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
2.75 11.79 4.25 2.57 5.35

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Effective Interest Rate on Debt % Get a 7-Day Free Trial 4.31 2.05 4.29 2.27 1.03

Competitive Comparison of Oncodesign Precision Medicine's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Oncodesign Precision Medicine's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Effective Interest Rate on Debt % falls into.


;
;

Oncodesign Precision Medicine Effective Interest Rate on Debt % Calculation

Oncodesign Precision Medicine's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  -0.439/( (8.827+7.581)/ 2 )
=-1  *  -0.439/8.204
=5.35 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=8.827 + 0
=8.827

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=7.196 + 0.385
=7.581

Oncodesign Precision Medicine's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2024 )+Total Debt  (Q: Dec. 2024 ))/ count )
=-1  *  -0.078/( (0+7.581)/ 1 )
=-1  *  -0.078/7.581
=1.03 %

where

Total Debt  (Q: Jun. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 0
=0

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=7.196 + 0.385
=7.581

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Oncodesign Precision Medicine  (XPAR:ALOPM) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Oncodesign Precision Medicine Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Effective Interest Rate on Debt %
Comparable Companies
XPAR:ALTAO XPAR:ALTME XPAR:ALTHX XPAR:ALINT XPAR:ALVIO XPAR:ALBPS XPAR:ALPAT XPAR:ALNFL XPAR:ALNEV XPAR:ALCOX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ZR8:Germany
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines